ABSTRACT
We apply a generalized logistic growth model, with time dependent parameters, to describe the fatality curves of the COVID-19 disease for several countries that exhibit multiple waves of infections. In the case of two waves only, the model parameters vary as a function of time according to a logistic function, whose two extreme values, i.e., for early and late times, characterize the first and second waves, respectively. For the multiple-wave model, the time-dependency of the parameters is likewise described by a multi-step logistic function with N intermediate plateaus, representing the N waves of the epidemic. We show that the theoretical curves are in excellent agreement with the empirical data for all countries considered here, namely: Brazil, Canada, Germany, Iran, Italy, Japan, Mexico, South Africa, Sweden, and US. The model also allows for predictions about the time of occurrence and severity of the subsequent waves. It is shown furthermore that the subsequent waves of COVID-19 can be generically classified into two main types, namely, standard and anomalous waves, according as to whether a given wave starts well after or well before the preceding one has subsided, respectively.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported in part by the following Brazilian agencies:CNPq, under Grants No. 303772/2017-4 (GLV), No. 312612/2019-2 (AMSM) and No. 305305/2019-0 (RO), and CAPES.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos